Biotech Stocks Poised for 2025 Rebound
Biotech stocks are poised for a rebound in 2025, driven by increased merger and acquisition activity, new drug approvals, and a looming patent cliff forcing large pharmaceutical companies to seek innovative biotech partners; however, investors should focus on specific companies rather than broad ind...
Biotech Stocks Poised for 2025 Rebound
Biotech stocks are poised for a rebound in 2025, driven by increased merger and acquisition activity, new drug approvals, and a looming patent cliff forcing large pharmaceutical companies to seek innovative biotech partners; however, investors should focus on specific companies rather than broad ind...
Progress
48% Bias Score
Johnson & Johnson Targets Autoimmune Diseases with Novel Therapies
Johnson & Johnson, a leader in immunology, is researching treatments for over 80 autoimmune and alloantibody diseases affecting nearly 240 million globally, focusing on three segments with a targeted approach to lower pathogenic IgG antibodies while preserving overall immune function, addressing a c...
Johnson & Johnson Targets Autoimmune Diseases with Novel Therapies
Johnson & Johnson, a leader in immunology, is researching treatments for over 80 autoimmune and alloantibody diseases affecting nearly 240 million globally, focusing on three segments with a targeted approach to lower pathogenic IgG antibodies while preserving overall immune function, addressing a c...
Progress
36% Bias Score
New Asthma Attack Drug Shows Promise
Researchers report Benralizumab, a new drug, is more effective than steroids in treating severe asthma attacks; targeting eosinophils, it showed significantly lower treatment failure rates (45% vs 74%) in a 158-person clinical trial, leading to fewer hospitalizations and improved patient outcomes.
New Asthma Attack Drug Shows Promise
Researchers report Benralizumab, a new drug, is more effective than steroids in treating severe asthma attacks; targeting eosinophils, it showed significantly lower treatment failure rates (45% vs 74%) in a 158-person clinical trial, leading to fewer hospitalizations and improved patient outcomes.
Progress
40% Bias Score
MariTide Trial Results and Market Reaction
Amgen's weight loss drug, MariTide, shows bone density loss in early trials, causing market uncertainty.
MariTide Trial Results and Market Reaction
Amgen's weight loss drug, MariTide, shows bone density loss in early trials, causing market uncertainty.
Progress
0% Bias Score
Animal Dewormer Shows Promise Against Cancer, but Large-Scale Trials Needed
Studies suggest the animal dewormer fenbendazole may shrink tumors in some human cancer patients, but larger clinical trials are needed to confirm its safety and effectiveness, given reports of severe side effects in some cases.
Animal Dewormer Shows Promise Against Cancer, but Large-Scale Trials Needed
Studies suggest the animal dewormer fenbendazole may shrink tumors in some human cancer patients, but larger clinical trials are needed to confirm its safety and effectiveness, given reports of severe side effects in some cases.
Progress
56% Bias Score
Russia Begins Human Trials of Personalized Cancer Vaccine
Russia is conducting human clinical trials for "EnteroMix," a personalized cancer vaccine using oncolytic viruses, targeting patients with solid tumors who have exhausted standard treatment options, offering a potentially revolutionary approach to cancer treatment.
Russia Begins Human Trials of Personalized Cancer Vaccine
Russia is conducting human clinical trials for "EnteroMix," a personalized cancer vaccine using oncolytic viruses, targeting patients with solid tumors who have exhausted standard treatment options, offering a potentially revolutionary approach to cancer treatment.
Progress
44% Bias Score
Psychedelic Drugs: FDA Approvals and Future of Mental Health Treatment
The FDA approval of Cybin's synthetic psilocybin for phase 3 trials, and MindMed's upcoming LSD trials for anxiety, signify progress despite recent setbacks in the psychedelic drug development sector.
Psychedelic Drugs: FDA Approvals and Future of Mental Health Treatment
The FDA approval of Cybin's synthetic psilocybin for phase 3 trials, and MindMed's upcoming LSD trials for anxiety, signify progress despite recent setbacks in the psychedelic drug development sector.
Progress
0% Bias Score
French Health Authority Rejects Early Access to Biogen's ALS Drug
The French health authority denied early access to Biogen's ALS drug Qalsody due to insufficient clinical trial data, sparking controversy and raising questions about its potential effectiveness.
French Health Authority Rejects Early Access to Biogen's ALS Drug
The French health authority denied early access to Biogen's ALS drug Qalsody due to insufficient clinical trial data, sparking controversy and raising questions about its potential effectiveness.
Progress
0% Bias Score